Press Releases

Multi-Institutional Report Shows That AI Cancer Mentor Dave Provides Valuable and Reliable Recommendations for Cancer Patients and Caregivers, With a Positive Validation Of 91.8%

NEW YORK, May 23, 2024 /PRNewswire/ -- Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that the American Society of Clinical Oncology (ASCO) has published an abstract in its 2024 Annual Meeting Book highlighting the positive... (continue reading...)

Relapse-free survival and overall survival were 82.5% and 100% at 12 months, respectively, in 37 patients with AML, an aggressive form of blood cancer

Non-relapse mortality at 12 months was 0%

Orca-T is currently being evaluated in a pivotal Phase 3 clinical trial at leading treatment centers across the U.S.

MENLO PARK, Calif.--(BUSINESS WIRE)-- Orca Bio, a biotechnology company committed to transforming the lives of patients through high-precision cell... (continue reading...)

INDIANAPOLIS, May 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting... (continue reading...)

• 54% of TKI-treated CML-patients received a PPI
• 66% of concomitant prescribing was by a different healthcare provider
• Crystalline dasatinib Cmax and AUC24 reduced by 96% and 88% respectively

STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of marketed drugs for the treatment of cancer announced today the online... (continue reading...)

Highlights include a 2024 Best of ASCO® oral abstract on unrelated donor blood stem cell transplantation, late-breaking oral abstract on combination sotorasib for patients with a treatment-resistant tumor mutation called KRAS G12C, and monotherapies for people with advanced cancers

LOS ANGELES--(BUSINESS WIRE)-- World-renowned physicians and researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States, will... (continue reading...)